Publications by authors named "David T Vistica"

Claim this Profile
B
Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets.
David G Covell, Anders Wallqvist, Susan Kenney, David T Vistica

PLoS One· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.
Susan Kenney, David T Vistica, Luke H Stockwin, Sandra Burkett, Melinda G Hollingshead

J Pediatr Hematol Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
David T Vistica, Melinda Hollingshead, Suzanne D Borgel, Susan Kenney, Luke H Stockwin

J Pediatr Hematol Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiling of alveolar soft-part sarcoma (ASPS).
Luke H Stockwin, David T Vistica, Susan Kenney, David S Schrump, Donna O Butcher

BMC Cancer· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma.
David T Vistica, Paula M Krosky, Susan Kenney, Mark Raffeld, Robert H Shoemaker

J Pediatr Hematol Oncol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.
Andrea I Loaiza-Pérez, Susan Kenney, Jamie Boswell, Melinda Hollingshead, Michael C Alley, David T Vistica

Mol Cancer Ther· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis